Bioprosthetic valve thrombosis (BPVT) is an important and potentially reversible cause of valvular dysfunction. This complication can occur many years after surgery and understanding of the precise mechanisms and risk factors is limited. Anticoagulation therapy has been demonstrated to be effective in improving BPVT. However, the optimal duration of therapy and the risk of recurrence are unknown. Herein, we describe two cases—one of late BPVT and one of recurrence of BPVT after cessation of anticoagulation therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Possible subclinical leaflet thrombosis in bioprosthetic aortic valves.N Engl J Med. 2016; 374: 1591-1592
- Outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically implanted valves: a prospective study.JACC Cardiovasc Interv. 2017; 10: 379-387
- Prosthetic heart valve thrombosis.J Am Coll Cardiol. 2016; 68: 2670-2689
- Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors.J Am Coll Cardiol. 2015; 66: 2285-2294
Published online: December 11, 2017
Accepted: November 29, 2017
Received in revised form: October 24, 2017
Received: June 26, 2017
© 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.